SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Chris Wilkins, A critical first assessment of the new pre-market approval regime for new psychoactive substances (NPS) in New Zealand, Addiction, 2014, 109, 10
  2. 2
    Gillinder Bedi, Guillermo A Cecchi, Diego F Slezak, Facundo Carrillo, Mariano Sigman, Harriet de Wit, A Window into the Intoxicated Mind? Speech as an Index of Psychoactive Drug Effects, Neuropsychopharmacology, 2014, 39, 10, 2340

    CrossRef

  3. 3
    Michael Singleton, John M. Stogner, Bryan Lee Miller, Awareness of Novel Drug Legality in a Young Adult Population, American Journal of Criminal Justice, 2014, 39, 3, 425

    CrossRef

  4. 4
    Toby Seddon, Drug policy and global regulatory capitalism: The case of new psychoactive substances (NPS), International Journal of Drug Policy, 2014,

    CrossRef

  5. 5
    Brendan Hughes, Paul Griffiths, Regulatory approaches to new psychoactive substances (NPS) in the European Union, Addiction, 2014, 109, 10
  6. 6
    Denise Walker, Clayton Neighbors, Thomas Walton, Adam Pierce, Lyungai Mbilinyi, Debra Kaysen, Roger Roffman, Spicing up the military: Use and effects of synthetic cannabis in substance abusing army personnel, Addictive Behaviors, 2014, 39, 7, 1139

    CrossRef

  7. 7
    Alex Stevens, Fiona Measham, The ‘drug policy ratchet’: why do sanctions for new psychoactive drugs typically only go up?, Addiction, 2014, 109, 8
  8. 8
    Chris Wilkins, Paul Sweetsur, Karl Parker, The impact of the prohibition of benzylpiperazine (BZP) “legal highs” on the availability, price and strength of BZP in New Zealand, Drug and Alcohol Dependence, 2014,

    CrossRef

  9. 9
    Luca Zamengo, Giampietro Frison, Chiara Bettin, Rocco Sciarrone, Understanding the risks associated with the use of new psychoactive substances (NPS): High variability of active ingredients concentration, mislabelled preparations, multiple psychoactive substances in single products, Toxicology Letters, 2014, 229, 1, 220

    CrossRef

  10. 10
    Marie Claire Van Hout, Tim Bingham, ‘Silk Road’, the virtual drug marketplace: A single case study of user experiences, International Journal of Drug Policy, 2013, 24, 5, 385

    CrossRef

  11. 11
    Karenza Moore, Paul I. Dargan, David M. Wood, Fiona Measham, Do Novel Psychoactive Substances Displace Established Club Drugs, Supplement Them or Act as Drugs of Initiation The relationship between Mephedrone, Ecstasy and Cocaine, European Addiction Research, 2013, 19, 5, 276

    CrossRef

  12. 12
    Paul Griffiths, Michael Evans-Brown, Roumen Sedefov, Getting up to speed with the public health and regulatory challenges posed by new psychoactive substances in the information age, Addiction, 2013, 108, 10
  13. 13
    Adam R. Winstock, Monica J. Barratt, Synthetic cannabis: A comparison of patterns of use and effect profile with natural cannabis in a large global sample, Drug and Alcohol Dependence, 2013, 131, 1-2, 106

    CrossRef

  14. 14
    Simon D. Brandt, Robin A. Braithwaite, Michael Evans-Brown, Andrew T. Kicman, Novel Psychoactive Substances, 2013,

    CrossRef

  15. 15
    Krzysztof Krajewski, Against excess, Addiction, 2012, 107, 11
  16. 16
    Janie Sheridan, Bruce Atmore, Bruce Russell, New Zealand to establish fit for purpose regulation for new psychoactive substances, Addiction, 2012, 107, 11
  17. 17
    Jeremy Parsons, No quick fix for legal highs, Addiction, 2012, 107, 11
  18. 18
    Tom P. Freeman, H. Valerie Curran, Supply always comes on the heels of demand: what effects do control strategies have on drug users themselves?, Addiction, 2012, 107, 11
  19. 19
    Peter Reuter, The dangerous charms of the unknown, Addiction, 2012, 107, 11